FTC Says "Orange Book" Abuse Blocks Drug Competition

By Kelly Lienhard · November 14, 2022, 6:46 PM EST

The Federal Trade Commission urged a Delaware federal court to remove a patent for narcolepsy drug distribution from federal regulators' list of approved drugs and the patents covering them, arguing the patent was improperly included and...

To view the full article, register now.

Documents

Case Information

Case Title

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

Case Number

1:21-cv-00691

Court

Delaware

Nature of Suit

Patent

Date Filed

May 12, 2021